The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.
 
Jeeyun Lee
No Relationships to Disclose
 
Johanna C. Bendell
No Relationships to Disclose
 
Sun Young Rha
No Relationships to Disclose
 
Yung-Jue Bang
Honoraria - Five Prime Therapeutics
 
Lee Clark
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Travel, Accommodations, Expenses - Five Prime Therapeutics; XenoPort
 
Hong Xiang
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics
 
Kristen L. Pierce
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics
 
Kartik Krishnan
Employment - Biomarin; Biomarin (I); Five Prime Therapeutics
Stock and Other Ownership Interests - Biomarin (I); Gilead Sciences (I)
 
Robert S. Sikorski
Employment - Five Prime Therapeutics
Leadership - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics
Travel, Accommodations, Expenses - Five Prime Therapeutics
 
Drew W. Rasco
Research Funding - Five Prime Therapeutics